中华核医学杂志
中華覈醫學雜誌
중화핵의학잡지
CHINESE JOURNAL OF NUCLEAR MEDICINE
2009年
3期
194-196
,共3页
陆云%刘兴党%李鼎%邓守真
陸雲%劉興黨%李鼎%鄧守真
륙운%류흥당%리정%산수진
抗原,肿瘤%抗原,肿瘤相关,碳水化合物%胰腺肿瘤
抗原,腫瘤%抗原,腫瘤相關,碳水化閤物%胰腺腫瘤
항원,종류%항원,종류상관,탄수화합물%이선종류
Antigens,neoplasms%Antigens,tumor-associated,carbohydrate%Pancreatic neoplasms
目的 对比分析组织多肽特异性抗原(TPS)与多个糖类抗原(CA)血清浓度,探讨TPS对胰腺癌的诊断价值.方法 血清标本来自慢性胰腺炎患者33例,非胰腺恶性肿瘤患者35例,胰腺癌患者34例.TPS测量采用酶联免疫吸附测定(ELISA);CA19-9和CA125测定采用化学发光免疫分析;CA50和CA242测定采用免疫放射分析法.测量数据采用SPSS 9.0统计软件进行统计分析.结果 胰腺癌患者血清TPS[(386.5±315.1)U/L]和CA19-9[(10 820.9±389.7)kU/L]均明显高于慢性胰腺炎患者[分别为(86.2±28.1)U/L,(61.5±24.7)kU/L;F=936.42和2217.09,P均<0.001].其中,TPS灵敏度为70.6%(48/68),特异性57.4%(39/68);CA19-9灵敏度为82.4%(28/34),特异性77.9%(53/68).联合使用TPS与CA19-9、CA50、CA125和CA242,可显著增加灵敏度(94.1%,32/34),减少漏诊率.结论 TPS作为CA19-9的有益补充,可提高诊断胰腺癌的灵敏度.
目的 對比分析組織多肽特異性抗原(TPS)與多箇糖類抗原(CA)血清濃度,探討TPS對胰腺癌的診斷價值.方法 血清標本來自慢性胰腺炎患者33例,非胰腺噁性腫瘤患者35例,胰腺癌患者34例.TPS測量採用酶聯免疫吸附測定(ELISA);CA19-9和CA125測定採用化學髮光免疫分析;CA50和CA242測定採用免疫放射分析法.測量數據採用SPSS 9.0統計軟件進行統計分析.結果 胰腺癌患者血清TPS[(386.5±315.1)U/L]和CA19-9[(10 820.9±389.7)kU/L]均明顯高于慢性胰腺炎患者[分彆為(86.2±28.1)U/L,(61.5±24.7)kU/L;F=936.42和2217.09,P均<0.001].其中,TPS靈敏度為70.6%(48/68),特異性57.4%(39/68);CA19-9靈敏度為82.4%(28/34),特異性77.9%(53/68).聯閤使用TPS與CA19-9、CA50、CA125和CA242,可顯著增加靈敏度(94.1%,32/34),減少漏診率.結論 TPS作為CA19-9的有益補充,可提高診斷胰腺癌的靈敏度.
목적 대비분석조직다태특이성항원(TPS)여다개당류항원(CA)혈청농도,탐토TPS대이선암적진단개치.방법 혈청표본래자만성이선염환자33례,비이선악성종류환자35례,이선암환자34례.TPS측량채용매련면역흡부측정(ELISA);CA19-9화CA125측정채용화학발광면역분석;CA50화CA242측정채용면역방사분석법.측량수거채용SPSS 9.0통계연건진행통계분석.결과 이선암환자혈청TPS[(386.5±315.1)U/L]화CA19-9[(10 820.9±389.7)kU/L]균명현고우만성이선염환자[분별위(86.2±28.1)U/L,(61.5±24.7)kU/L;F=936.42화2217.09,P균<0.001].기중,TPS령민도위70.6%(48/68),특이성57.4%(39/68);CA19-9령민도위82.4%(28/34),특이성77.9%(53/68).연합사용TPS여CA19-9、CA50、CA125화CA242,가현저증가령민도(94.1%,32/34),감소루진솔.결론 TPS작위CA19-9적유익보충,가제고진단이선암적령민도.
Objective To compare the diagnostic value of tissue polypeptide specific antigen (TPS) in serum, with the carbohydrate antigens (CA) 19-9, CA50, CA125 and CA242 in pancreatic carci-noma. Methods Serum TPS was measured with enzyme linked immunosorbent assay (ELISA). CA19-9 and CA125 were measured with chemiluminescent immunoassay. CAS0 and CA242 were measured with im-munoradiometric assay in 33 patients with pancreatitis, 34 patients with pathologically proven pancreatic car-cinoma, and 35 patients with non-pancreatic malignancies. Statistic analysis was carried out with SPSS 9.0 software. Results Patients with pancreatic carcinoma had relatively higher levels of TPS [(386.5± 315. 1) U/L] and CA19-9 [(10 820.9 ± 389.7) kU/L] when compared with patients with pancreatitis [(86. 2 ± 28.1) U/L and (61.5 ± 24.7) kU/L, respectively; F = 936. 42, P < 0. 001 ; F = 2217. 09, P < 0. 001], with a sensitivity and a specificity of 70.6% (48/68) and 57.4% (39/68), respectively, for TPS, and 82.4% (28/34) and 77.9% (53/68), respectively, for CA19-9. Diagnostic performance was further improved when TPS was assayed in combination with CA19-9, CA50, CA12.5 and CA242. Conclusion Serum TPS has an incremental value in complementing CA19-9 in the diagnosis of pancreatic carcinoma.
